OS Therapies reports statistically significant interim 3-year OS benefit
OS Therapies (OSTX) announced a statistically significant benefit for OST-HER2-treated patients in interim 3-year overall survival analysis from its Phase 2b pulmonary metastatic osteosarcoma trial.